University of Padua-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2019

  1. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?

    Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 13, Núm. 4, pp. 2723-2725

  2. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential

    Cardiovascular Diabetology, Vol. 18, Núm. 1

2016

  1. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

    European Heart Journal, Supplement, Vol. 18, pp. C2-C12

2015

  1. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy

    Atherosclerosis Supplements, Vol. 19, pp. 1-12

2014

  1. Residual macrovascular risk in 2013: What have we learned?

    Cardiovascular Diabetology, Vol. 13, Núm. 1